Ultra-Expensive Drugs And Medicare Part D: Spending And Beneficiary Use Up Sharply

So-Yeon Kang¹, Daniel Polsky², Jodi B Segal³, Gerard F Anderson⁴

Affiliations

¹ So-Yeon Kang (Soyeon.Kang@jhu.edu) is a PhD student in the Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, in Baltimore, Maryland.
² Daniel Polsky is the Bloomberg Distinguished Professor of Health Economics in the Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, and the Johns Hopkins Carey Business School.
³ Jodi B. Segal is a professor of medicine at the Johns Hopkins School of Medicine and a professor in the Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health.
⁴ Gerard F. Anderson is a professor of health policy and management and a professor of international health at the Johns Hopkins Bloomberg School of Public Health, a professor of medicine at the Johns Hopkins School of Medicine, and director of the Johns Hopkins Center for Hospital Finance and Management.

PMID: 34097507
DOI: 10.1377/hlthaff.2020.00896

Ultra-Expensive Drugs And Medicare Part D: Spending And Beneficiary Use Up Sharply

So-Yeon Kang et al. Health Aff (Millwood). 2021 Jun.

. 2021 Jun;40(6):1000-1005.

doi: 10.1377/hlthaff.2020.00896.

Authors

So-Yeon Kang¹, Daniel Polsky², Jodi B Segal³, Gerard F Anderson⁴

Affiliations

¹ So-Yeon Kang (Soyeon.Kang@jhu.edu) is a PhD student in the Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, in Baltimore, Maryland.
² Daniel Polsky is the Bloomberg Distinguished Professor of Health Economics in the Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, and the Johns Hopkins Carey Business School.
³ Jodi B. Segal is a professor of medicine at the Johns Hopkins School of Medicine and a professor in the Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health.
⁴ Gerard F. Anderson is a professor of health policy and management and a professor of international health at the Johns Hopkins Bloomberg School of Public Health, a professor of medicine at the Johns Hopkins School of Medicine, and director of the Johns Hopkins Center for Hospital Finance and Management.

PMID: 34097507
DOI: 10.1377/hlthaff.2020.00896

Abstract

The proliferation of "ultra-expensive" drugs has sparked debate on their sustainability and affordability. Medicare Part D's share of annual spending on these drugs increased by 1,170 percent between 2012 and 2018, largely because the number of beneficiaries receiving them increased during this period.

PubMed Disclaimer

Cited by

Trends in Integration Between Physician Organizations and Pharmacies for Self-Administered Drugs.
Kakani P, Cutler DM, Rosenthal MB, Keating NL. Kakani P, et al. JAMA Netw Open. 2024 Feb 5;7(2):e2356592. doi: 10.1001/jamanetworkopen.2023.56592. JAMA Netw Open. 2024. PMID: 38373001 Free PMC article.
The challenges of access to innovative medicines with limited evidence in the European Union.
Vallano A, Pontes C, Agustí A. Vallano A, et al. Front Pharmacol. 2023 Aug 31;14:1215431. doi: 10.3389/fphar.2023.1215431. eCollection 2023. Front Pharmacol. 2023. PMID: 37719853 Free PMC article. Review.
Incorporating Added Therapeutic Benefit and Domestic Reference Pricing Into Medicare Payment for Expensive Part B Drugs.
Anderson KE, DiStefano MJ, Liu A, Mattingly TJ 2nd, Socal MP, Anderson GF. Anderson KE, et al. Value Health. 2023 Sep;26(9):1381-1388. doi: 10.1016/j.jval.2023.05.018. Epub 2023 Jun 5. Value Health. 2023. PMID: 37285915 Free PMC article.
Role of Specialty Drugs in Rising Drug Prices for Medicare Part D.
Hayford TB. Hayford TB. JAMA Health Forum. 2024 May 3;5(5):e241188. doi: 10.1001/jamahealthforum.2024.1188. JAMA Health Forum. 2024. PMID: 38787543 Free PMC article.
"Comprehensive Healthcare for America": Using the Insights of Behavioral Economics to Transform the U. S. Healthcare System.
Sorum PC, Stein C, Moore DL. Sorum PC, et al. J Law Med Ethics. 2023;51(1):153-171. doi: 10.1017/jme.2023.52. Epub 2023 May 25. J Law Med Ethics. 2023. PMID: 37226742 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Atypon
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Ultra-Expensive Drugs And Medicare Part D: Spending And Beneficiary Use Up Sharply

Affiliations

Ultra-Expensive Drugs And Medicare Part D: Spending And Beneficiary Use Up Sharply

Authors

Affiliations

Abstract

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical